Uncover key drivers, emerging technologies, and competitive movements shaping the atherosclerosis drugs market from 2026–2035 with trusted insights from The Business Research Company
How is the Atherosclerosis Drugs Market size predicted to change over the forecast window of 2026–2035?
The size of the atherosclerosis drugs market has shown consistent expansion over recent years. This market is projected to expand from $50.91 billion in 2025 to $52.45 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.0%. Historically, this growth has been driven by several factors, including the increasing occurrence of cardiovascular diseases, heightened public awareness regarding heart health, the widespread use of statins and other cholesterol-reducing medications, governmental efforts promoting cardiovascular care, and the expansion of hospital and retail pharmacy infrastructure.
The atherosclerosis drugs market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $61.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.9%. Factors contributing to this growth during the forecast timeframe include the expansion of precision medicine in cardiovascular care, a greater uptake of digital health monitoring tools, an increasing need for combination therapies, the growing elderly population, and advancements in new anti-atherosclerosis drug categories. Key trends expected over the forecast period encompass personalized atherosclerosis treatments, combination drug formulations, support for minimally invasive treatments, proactive cardiovascular healthcare, and a focus on patient adherence and digital monitoring.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp
Which Drivers Are Contributing To The Expansion Of The Atherosclerosis Drugs Market?
The increasing incidence of cardiovascular diseases is anticipated to stimulate the growth of the atherosclerosis drug market moving forward. Cardiovascular diseases are conditions that impact the heart and blood vessels, whereas atherosclerosis is defined by the accumulation of fats, cholesterol, and other substances on the artery walls. This plaque buildup within the arteries, characteristic of atherosclerosis, leads to cardiovascular issues such as coronary heart disease and stroke. Atherosclerosis drugs are utilized to address cardiovascular diseases by lessening the risk of complications and controlling underlying conditions like elevated cholesterol levels and the formation of blood clots. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Thus, the widespread occurrence of cardiovascular diseases is expected to propel the atherosclerosis drug market.
What Segment Classifications Make Up The Atherosclerosis Drugs Market?
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
Which Innovation Trends Are Advancing Developments Within The Atherosclerosis Drugs Market?
Leading companies in the atherosclerosis drugs market are innovating by creating new products, such as anti-inflammatory medications, to boost their profitability. Atherosclerosis anti-inflammatory drugs are defined as medicines specifically formulated to mitigate inflammation associated with atherosclerosis, a condition characterized by the accumulation of plaque in arteries. For instance, in June 2023, AGEPHA Pharma, a Europe-based manufacturer of medical products, launched LODOCO. LODOCO (colchicine, 0.5 mg tablet) has received approval from the U.S. FDA as the inaugural anti-inflammatory atheroprotective cardiovascular treatment. This drug has demonstrated its effectiveness in lowering the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. LODOCO addresses residual inflammation, a critical component in atherosclerotic cardiovascular disease (ASCVD). Approved for use either independently or in conjunction with cholesterol-lowering medications, this drug represents a significant breakthrough in cardiovascular care.
Which Major Firms Are Strengthening Their Position In The Atherosclerosis Drugs Market?
Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Which Region Shows The Strongest Potential For Future Expansion In The Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Atherosclerosis Drugs Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp
Browse Through More Reports Similar to the Global Atherosclerosis Drugs Market 2026, By The Business Research Company
Atherosclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Atorvastatin Market Report 2026
https://www.thebusinessresearchcompany.com/report/atorvastatin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model